A number of companies are using the lessons and technologies of traditional genomics--the microarray chief among them--to delve into the more challenging world of functional genomics and proteomics.

Cancer treatment is becoming more personalised. By considering a patient’s unique genetic and molecular profile, along with their lifestyle and environmental factors, doctors can make more accurate ...

Cancer drug development is being stymied by a lack of two critical elements: novel gene targets and biomarkers for stratifying patients in clinical trials. MEDiC Life Sciences is addressing both gaps.

A study has used a multidisciplinary high-throughput functional genomics approach to identify and functionally validate dozens of genes that could cause or protect against Parkinson's disease. Many ...

Functional genomics studies investigate genetic changes that contribute to disease development and progression with an eye toward making better therapies and diagnostics. In a new laboratory at the ...

There are an estimated 6,000 Mendelian diseases, most of which still lack cures. Gene editing is an essential technology for studies aimed at generating data about disease-causing gene mutations and ...

A research team led by Professor Simona Giunta at the University of Rome La Sapienza has produced the first reference-quality ...

Now that the human genome has been sequenced to a rough draft, the scientific community is looking down the road to what's next. Last month's announcement (see page 1) spotlights a nascent area of ...

CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors. Sudocetaxel zendusortide (TH1902), a novel ...